These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767 [TBL] [Abstract][Full Text] [Related]
43. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation. Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599 [TBL] [Abstract][Full Text] [Related]
44. Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation. Bernarde C; Keravec M; Mounier J; Gouriou S; Rault G; Férec C; Barbier G; Héry-Arnaud G PLoS One; 2015; 10(4):e0124124. PubMed ID: 25853698 [TBL] [Abstract][Full Text] [Related]
45. Overexpression of RANK and M-CSFR in Monocytes of G551D-Bearing Patients with Cystic Fibrosis. Velard F; Jourdain ML; Abdallah D; Jacquot J; Ronan N; McCarthy Y; Flanagan E; Plant B Am J Respir Crit Care Med; 2018 Oct; 198(7):968-970. PubMed ID: 29940131 [No Abstract] [Full Text] [Related]
46. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. Ramsey BW; Davies J; McElvaney NG; Tullis E; Bell SC; Dřevínek P; Griese M; McKone EF; Wainwright CE; Konstan MW; Moss R; Ratjen F; Sermet-Gaudelus I; Rowe SM; Dong Q; Rodriguez S; Yen K; Ordoñez C; Elborn JS; N Engl J Med; 2011 Nov; 365(18):1663-72. PubMed ID: 22047557 [TBL] [Abstract][Full Text] [Related]
47. Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation. Pohl K; Nichols DP; Taylor-Cousar JL; Saavedra MT; Strand MJ; Nick JA; Bratcher PE PLoS One; 2018; 13(12):e0209026. PubMed ID: 30540818 [TBL] [Abstract][Full Text] [Related]
48. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation. Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026 [No Abstract] [Full Text] [Related]
49. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Sawicki GS; McKone EF; Pasta DJ; Millar SJ; Wagener JS; Johnson CA; Konstan MW Am J Respir Crit Care Med; 2015 Oct; 192(7):836-42. PubMed ID: 26132840 [TBL] [Abstract][Full Text] [Related]
50. CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials. Bell SC; Barry PJ; De Boeck K; Drevinek P; Elborn JS; Plant BJ; Minić P; Van Braeckel E; Verhulst S; Muller K; Kanters D; Bellaire S; de Kock H; Geller DE; Conrath K; Van de Steen O; van der Ent K J Cyst Fibros; 2019 Sep; 18(5):700-707. PubMed ID: 31056441 [TBL] [Abstract][Full Text] [Related]
51. Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients. McCormick J; Cho DY; Lampkin B; Richman J; Hathorne H; Rowe SM; Woodworth BA Int Forum Allergy Rhinol; 2019 Mar; 9(3):292-297. PubMed ID: 30472785 [TBL] [Abstract][Full Text] [Related]
52. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL; N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692 [TBL] [Abstract][Full Text] [Related]
53. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial. Quittner A; Suthoff E; Rendas-Baum R; Bayliss MS; Sermet-Gaudelus I; Castiglione B; Vera-Llonch M Health Qual Life Outcomes; 2015 Jul; 13():93. PubMed ID: 26135562 [TBL] [Abstract][Full Text] [Related]
54. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ΔF508 CFTR from thermal instability. Liu X; Dawson DC Biochemistry; 2014 Sep; 53(35):5613-8. PubMed ID: 25148434 [TBL] [Abstract][Full Text] [Related]
55. Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR. Birket SE; Davis JM; Fernandez-Petty CM; Henderson AG; Oden AM; Tang L; Wen H; Hong J; Fu L; Chambers A; Fields A; Zhao G; Tearney GJ; Sorscher EJ; Rowe SM Am J Respir Crit Care Med; 2020 Nov; 202(9):1271-1282. PubMed ID: 32584141 [No Abstract] [Full Text] [Related]
56. GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN). van Koningsbruggen-Rietschel S; Conrath K; Fischer R; Sutharsan S; Kempa A; Gleiber W; Schwarz C; Hector A; Van Osselaer N; Pano A; Corveleyn S; Bwirire D; Santermans E; Muller K; Bellaire S; Van de Steen O J Cyst Fibros; 2020 Mar; 19(2):292-298. PubMed ID: 31594690 [TBL] [Abstract][Full Text] [Related]
57. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Southern KW; Murphy J; Sinha IP; Nevitt SJ Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662 [TBL] [Abstract][Full Text] [Related]
58. Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis. O'Reilly R; Elphick HE Drug Des Devel Ther; 2013; 7():929-37. PubMed ID: 24039402 [TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. De Boeck K; Munck A; Walker S; Faro A; Hiatt P; Gilmartin G; Higgins M J Cyst Fibros; 2014 Dec; 13(6):674-80. PubMed ID: 25266159 [TBL] [Abstract][Full Text] [Related]
60. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM; N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]